Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹537 Cr
P/E Ratio
31.61
P/B Ratio
0.49
Industry P/E
52.8
Debt to Equity
0.59
ROE
0.47 %
ROCE
6.54 %
Div. Yield
0 %
Book Value
48.41
EPS
0.76
CFO
₹1,576.07 Cr
EBITDA
₹1,914.63 Cr
Net Profit
₹240.10 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Nectar Lifescience
| -38.89 | -3.68 | -39.40 | -29.94 | -8.36 | 9.99 | -3.62 |
|
BSE Healthcare
| -5.00 | 1.86 | -0.55 | 24.06 | 20.25 | 23.06 | 9.92 |
|
BSE Small Cap
| -10.06 | 4.18 | -3.85 | 5.99 | 18.99 | 35.51 | 15.86 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Nectar Lifescience
| 19.94 | 30.96 | -8.40 | 15.27 | 93.52 | -41.16 | -48.38 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 297.80 | 3,252.61 | 61.76 | 24.79 | |
| 840.00 | 4,288.30 | 38.87 | 9.22 | |
| 2,321.70 | 3,837.55 | 48.5 | 23 | |
| 640.20 | 4,557.01 | -- | 4.09 |
No Review & Analysis are available.
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company's active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline,... cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company provides menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India. Read more
Incorporated
1995
Chairman
Sanjiv Goyal
Managing Director
Sanjiv Goyal
Headquarters
Mohali Dist, Punjab
Website
Looking for more details about Nectar Lifesciences Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Nectar Lifesciences Ltd stood at ₹ 2,183 Cr as on 31-Dec-24
The share price of Nectar Lifesciences Ltd is ₹23.82 (NSE) and ₹23.83 (BSE) as of 24-Apr-2025 15:04 IST. Nectar Lifesciences Ltd has given a return of -8.36% in the last 3 years.
Nectar Lifesciences Ltd has a market capitalisation of ₹ 537 Cr as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Nectar Lifesciences Ltd is 0.49 times as on 24-Apr-2025, a 82% discount to its peers’ median range of 2.74 times.
The P/E ratio of Nectar Lifesciences Ltd is 31.61 times as on 24-Apr-2025, a 40% discount to its peers’ median range of 52.80 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Nectar Lifesciences Ltd and enter the required number of quantities and click on buy to purchase the shares of Nectar Lifesciences Ltd.
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company's active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company provides menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
The promoters of Nectar Lifesciences Ltd are SANJIV GOYAL and SANJIV (HUF). They collectively own 44.35 per cent of the total equity. The chairman of the company is Sanjiv Goyal
The promoters of Nectar Lifesciences Ltd have pledged 44.35% of the total equity as on Mar-25.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
4,325
|
|
|
3,932
|
|
|
3,634
|
|
|
3,445
|
| Nectar Lifesciences Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
1.58
|
|
Operating margin(%)
|
6.83
|
|
Net Margin(%)
|
1.01
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Nectar Lifesciences Ltd was ₹17 Cr.
₹1.06
(
